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Abstract 
 
Holoprosencephaly (HPE) is the most common malformation of the human 
forebrain, and may be due to cytogenetic anomalies, teratogens, occur in the context of a 
syndrome, or be due to mutations in single genes associated with non-syndromic HPE.  
Mutations in ZIC2, a transcription factor located on chromosome 13q32, are the second-
most common cause of non-syndromic, non-chromosomal HPE. Blood samples from 
over 1000 individuals with HPE-spectrum disorders and their relatives were analyzed for 
sequence variations in ZIC2. We examined clinical details and included all other known 
previously published and unpublished cases of mutations in ZIC2 through a literature 
search and collaboration with other centers.  We find mutations in ZIC2 in 8% of 
probands with HPE, and describe 153 individuals from 116 unrelated kindreds, including 
137 patients with molecularly-determined mutations in ZIC2 and 16 patients with 
deletions of the ZIC2 locus.  Unlike HPE due to mutations in other genes, the vast 
majority of cases are sporadic and the proportional distribution of HPE types differs 
significantly from previously published analyses of non-chromosomal non-syndromic 
HPE.  Furthermore, we describe a novel facial phenotype in patients with mutations in 
ZIC2 which includes bitemporal narrowing, upsplanting palpebral fissures, a short nose 
with anteverted nares, and a broad and well-demarcated philtrum, and large ears.   This 
phenotype is distinct from the standard facial dysmorphisms associated with non-
chromosomal, non-syndromic HPE.   Our findings show that HPE due to mutations in 
ZIC2 is distinct from that due to mutations in other genes.  This may shed light on the 
mechanisms that contribute to the formation of the face and the forebrain and may help 
direct genetic counseling and diagnostic strategies.  
Manuscript 
Holoprosencephaly (HPE) is the most common malformation of the human 
forebrain, and results from failed or incomplete forebrain cleavage early in gestation.  
HPE occurs in 1 in 250 gestations, though the vast majority of conceptions with HPE do 
not survive to birth
1,2
.  HPE is categorized by the degree of forebrain separation into 
alobar, in which there is no interhemispheric division, semilobar, and lobar HPE, from 
the most to least severe type.  More recently, middle interhemispheric variant (MIHV) 
HPE has also been described, which includes failed separation of the posterior frontal and 
parietal lobes
3-6
. The distribution of HPE types in both living patients and deceased 
fetuses with non-chromosomal, non-syndromic HPE has been estimated to be 22% 
alobar, 45% semilobar, and 33% lobar HPE
7
. 
 Common clinical features among patients with HPE include neurological 
impairment (often severe), seizures, diabetes insipidus, and characteristic dysmorphic 
facies.  Traditionally, it is thought that in HPE “the face predicts the brain”: in other 
words, more severe craniofacial anomalies correlate with more severe neuroanatomic 
findings.
4
  At the most severe end of the spectrum, facial features in patients with alobar 
HPE may include cyclopia and a proboscis (a tubular nasal structure located above the 
fused eyes).  Other, more common facial dysmorphisms in less-severely affected patients 
include microcephaly (though hydrocephalus can lead to macrocephaly), hypotelorism, a 
flat nasal bridge, and cleft lip and/or palate.  At the least severe end of the spectrum, 
termed microform HPE, patients may have subtle features such as mild microcephaly, 
hypotelorism, single maxillary central incisors (SMCI) without appreciable CNS 
anomalies on conventional neuroimaging.   These individuals are often identified due to 
the presence of a severely affected relative
6,8-9
. 
HPE is etiologically heterogeneous, and may be caused by cytogenetic anomalies, 
teratogenic influences, occur in the context of a syndrome, or be due to mutations in one 
of over 10 HPE-associated genes
6-8,10-12
.  In patients with HPE who have a normal 
chromosome analysis, a typical initial diagnostic strategy is to screen for mutations in 
four genes: SHH [MIM 600725], ZIC2 [MIM 603073], SIX3 [MIM 603714], and TGIF 
[MIM 602630]. Mutations in these genes can arise de novo or may be found in multiple 
members of large families segregating HPE-spectrum anomalies.  In large kindreds, 
family studies demonstrate the incomplete penetrance and highly variable expressivity of 
these mutations
3-4,6,13
.  
ZIC2, located at chromosome 13q32, was first identified as an HPE candidate 
gene due to individuals with brain anomalies who were found to have deletions involving 
the long arm of chromosome 13.  Subsequent analysis of patients with HPE identified 
mutations in ZIC2
14-16
. Mutations in this gene have previously been thought to be the 
second-most-common identified cause of non-chromosomal non-syndromic HPE (after 
mutations in SHH). In recent estimates, at least 3% of probands with HPE have mutations 
in ZIC2
6,17
. ZIC2 codes for a transcription factor which plays several roles in neurological 
development.  Early in development, ZIC2 is predicted to play a role in axial midline 
establishment; later, ZIC2 appears to affect the development of the dorsal 
telencephalon
18,19
.  This latter role may explain the occurrence of neural tube defects in 
individuals with mutations in ZIC2, as well as the presence of MIHV-type HPE, though 
this type can be seen in HPE due to mutations in other genes as well
20
. Mouse models 
show that complete absence of Zic2 activity results in HPE due to mid-gastrulation 
failure of axial midline development, homozygous hypomorphic alleles result in normal 
gastrulation but dorsal forebrain malformations at later stages, and heterozygotes for null 
alleles are phenotypically normal. However, features in homozygous null mice may 
recapitulate the entire spectrum of HPE severity, suggesting that the phenotypic 
consequences of mutations depend on the perturbed developmental stage and may be 
affected by interacting genes
17,19,21-22
. Of note, it has been suggested that mutations in 
ZIC2 may result in HPE, but often do not result in facial features typically seen in human 
patients with HPE due to mutations in other genes
23
. 
Here we present clinical and genetic data on all known individuals with mutations 
in ZIC2, over half of whom were identified through our laboratory via direct sequencing.  
We also present data on individuals with deletions of the ZIC2 locus ascertained by 
Multiplex Ligation-dependent Probe Amplification (MLPA) and Fluorescence in Situ 
Hybridization (FISH), chromosome analysis, or by oligonucleotide array comparative 
genomic hybridization.  Through this comprehensive evaluation, we can identify specific 
characteristics of these individuals that can differentiate the phenotypic findings in 
patients with HPE due to ZIC2 mutations from patients with HPE due to other genetic 
causes.   
 
Blood samples from approximately 800 individuals with HPE-spectrum disorders 
and their relatives were collected prospectively over 18 years.  These samples were 
analyzed for potential sequence variations in the ZIC2 gene under our NHGRI-approved 
brain research protocol after appropriate consent had been obtained.  A strategy for 
screening the ZIC2 gene has previously been described
17
.  Clinical history, photographs, 
and neuroimaging were reviewed where available, again after appropriate consent was 
obtained.  Three patients were seen at the National Institutes of Health for a 
comprehensive evaluation.  Collaborators sent us de-identified clinical and laboratory 
data on patients with identified mutations in ZIC2.   
A Medline search was conducted to find previously reported cases of 
holoprosencephaly due to mutations in ZIC2.  The key words and patient terms included 
“ZIC2”, “holoprosencephaly”, “HPE”, “13q”, and “13q32”.  References were also 
obtained from papers found through the literature search.  As loci nearby ZIC2 may 
contribute to brain malformations and there have been numerous reported cases of 
deletions of 13q with unreported clinical and genetic characterizations, only cases which 
had clear HPE and definitive deletion of the ZIC2 locus without involvement of other 
chromosomes were considered. Cases were used from the following papers and abstracts: 
[Brown et al., 1993]; [Brown et al., 1995]; [Brown et al., 1998]; [Chen et al., 1998]; 
[Nanni et al., 2000]; [Gutierrez et al., 2001]; [Orioli et al., 2001];  [Brown et al., 2001]; 
[Marcorelles et al., 2002];  [Dubourg et al., 2004]; [Brown et al., 2005]; [Júnior et al., 
2006]; [A. Paulussen et al., 2008, Eur. Soc. of Hum. Genet., abstract.]; [Roessler et al., 
2009]; [Quélin et al., 2009]
14-16,23-32
.  
 
We describe a total of 153 patients, including 137 patients from 100 unrelated 
kindreds with molecularly-determined mutations in ZIC2, 7 patients with deletions of 
ZIC2 ascertained by FISH testing and 9 patients with deletions of ZIC2 ascertained by 
chromosome analysis or by oligonucleotide microarray.  By direct sequencing of DNA 
samples of an unselected group of unrelated patients with HPE, 8.25% (99/1200) have 
mutations in ZIC2 (NIH: 49/285; Rennes: 41/532; Maastricht: 9/86).    Additional cases 
among the approximately 800 tested in our laboratory were ascertained through screening 
methodology, including screening methods involving single-strand conformational 
polymorphism (SSCP) analysis and denaturing high-performance liquid chromatography 
(dHPLC).   
Of note, in the descriptions below, unless otherwise stated, results refer only to 
individuals with molecularly determined mutations in ZIC2.  Denominators differ among 
findings, as the prevalence of each phenotypic manifestation was calculated only where 
data was available for that specific finding.  A summary of all patients is presented in the 
Supplementary Table.   
Inheritance 
Among probands in whom parents were available for testing, mutations were found to be 
de novo in 74% (49/66), maternally inherited in 18% (12/66), and paternally-inherited in 
8% (5/66) of patients.  There were no kindreds in which mutations or affected individuals 
were identified in more than 2 generations.  However, in 4 cases, pedigree analysis 
showed that a mutation appeared to be inherited from a parent who had multiple affected 
children but for whom mutation testing was negative, implying either allele drop-out or, 
more likely, germline mosaicism.   
HPE type  
Prevalences of HPE types for both all described individuals and probands are presented 
as tables 1 and 2.  Among patients with HPE, the distribution of classic HPE types (not 
including MIHV-type HPE) among patients with mutations in ZIC2 differs significantly 
from a previously published analysis of HPE distribution among patients with non-
chromosomal, non-syndromic HPE (χ2 = 16.401; p = 0.0003)7. Patients with mutations in 
ZIC2 had a higher prevalence of more severe HPE types.  Examples of characteristic 
findings on neuroimaging are shown in Figure 1. 
Table 1.  Prevalences of HPE types.   
HPE type Patients with 
mutations in 
ZIC2 (%) 
(n = 137) 
Patients with 
deletion of 
ZIC2 (%) (n = 
16) 
Alobar  21 38 
Semilobar 32 19 
Lobar 8 7 
MIHV 3 0 
Microform 4 0 
None 5 0 
Unknown 26 38 
 
Table 2. Prevalences of HPE types among probands with known HPE type. 
HPE 
Type 
Patients with 
mutations in 
ZIC2 (%) 
 (n = 83) 
Patients with 
deletion of 
ZIC2 (%) (n = 
10) 
Alobar 33 60 
Semilobar 51 30 
Lobar 12 10 
MIHV 5 0 
Clinical Features 
Among all individuals with mutations (including both probands and relatives of 
probands) for whom gender was known, 52% (61/118) were female and 48% (57/118) 
were male.  Among probands for whom gender was known, 51% (43/84) were female 
and 49% (41/84) were male.  There was no statistically significant difference between 
genders for either all individuals or probands alone.   
 Patients with recognizable brain anomalies invariably had some degree of 
neurological impairment.  Of 66 families tested, 18 parents were identified as having 
mutations initially found in their severely-affected children; of those who were 
subsequently fully examined, only 2 parents were not found to have mild features of 
microform HPE.  The overall penetrance of phenotypic manifestations (including 
microform HPE) due to mutations in ZIC2 is estimated to be 96%; the prevalence of 
brain anomalies is estimated to be 90%.   
While many individuals who received a full genetics evaluation had facial 
dysmorphisms, 67% (39/58) of patients with mutations in ZIC2 did not display typical 
HPE facial features such as hypotelorism, flat nasal bridge, cleft lip/palate, or SMCI, 
features frequently seen in patients with mutations in genes such as SHH and SIX3
20 
. No 
patients had facial findings at the most severe end of the spectrum, such as cyclopia or 
synophthalmia, though one patient with semilobar HPE was described as having a 
proboscis.  A review of photos (figure 2) of available probands (n = 30) with mutations in 
ZIC2 revealed a common phenotype in many patients consisting of bitemporal narrowing, 
upsplanting palpebral fissures, a short nose with anteverted nares, broad and well-
demarcated philtrums, and relatively large ears, even accounting for microcephaly (Table 
3).  Although additional photos were not available for review, a similar facial phenotype 
was independently described by collaborators (S.M., S.O., CNRS Génétique et 
Développement, Université de Rennes/ Service de génétique clinique, CHU Hôpital Sud, 
Rennes, France).  On review, this facial phenotype also occurs in previously published 
patients with mutations in ZIC2
16,23
.  Facial clefts, ranging from cleft lip and palate to a 
small unilateral nostril cleft, were described in 10% (7/69), while 17% (12/69) did not 
have clefts, but had high palates.   
Table 3.  Description of common dysmorphic features in probands shown in Figure 2.   
Patient  HPE type BN USPF FNB SNAN BDP LE Other Reference 
1 A + + + + +  Synophrys This 
report 
2 A  + + +    This 
report 
3 A + +  + +  Tall 
forehead 
This 
report 
4 A + +   +   This 
report 
5 A + + + + +   [16] 
6 A  +    + Sloping 
forehead 
[16] 
7 S  +  +    This 
report 
8 S + + + + +   This 
report 
9 S  +  + +   This 
report 
10 S + + + + + + Tall, broad 
forehead 
This 
report 
11 S +    +  Tall, 
narrow 
This 
report 
head 
12 S  +  + + + Slight 
synophrys, 
epicanthal 
folds, 
cupid-bow 
upper lip 
This 
report 
13 S  + +    Broad 
forehead 
This 
report 
14 S + +  +  +  This 
report 
15 S  +  +  +  This 
report 
16 S  +  +  + Synophrys This 
report 
17 S  +    + Synophrys This 
report 
18 S  + + +    This 
report 
19 S  +  +  +  This 
report 
20 S + +   + + Tall 
forehead 
This 
report 
21 S  +      This 
report 
22 S + +  +  + Tall 
forehead 
[23] 
23 S + +  + +   [23] 
24 S + + + +   Triangular 
mouth, 
myopathic 
facies 
[23] 
25 L + + + +    [23] 
26 MIHV  +  +  +  This 
report 
27 MIHV  +  + +   This 
report 
28 MIHV  + +  +   [23] 
29 Unknown  +  +  + Sloping 
forehead 
This 
report 
30 Unknown + +  + +  Tall  
forehead 
This 
report 
BN: Bitemporal narrowing; USPF: Upslanting palpebral fissures; FNB: Flat nasal bridge; 
SNAN: Short nose and/or anteverted nares; BDP: Broad or deep philtrum; LE: Large ears 
 
In terms of neurological defects beyond HPE, 12% (11/93) of individuals had 
hydrocephalus, and 4% (4/93) were reported as having neural tube defects.  Finally, in 
terms of non-neurological manifestations, 14% had skeletal anomalies, 9% had cardiac 
anomalies, 7% had renal anomalies, 7% had genital anomalies, 4% had gastrointestinal 
anomalies, and 4% had pulmonary anomalies (n =76).  Five percent had  more than 3 
congenital anomalies in these systems, including complex congenital heart, renal, and 
skeletal abnormalities.    
Genotypic and functional analysis 
The molecular findings among patients with mutations in ZIC2 have been recently and 
extensively analyzed
17
.  Among kindreds with molecularly-identified mutations, 84% 
(84/100) were unique. One mutation, which resulted in an alanine expansion and which 
has been show to result in greatly reduced function, occurred in 11 apparently unrelated 
kindreds.  
 Among the 100 unrelated kindreds with molecularly-demonstrated mutations, 
38% (38/100) had frameshift mutations, 21% (21/100) had missense mutations, 16% 
(16/100) were nonsense mutations, 16% (16/100) were in-frame duplications, 5% (5/100) 
were predicted to result in alternative splicing, 3% (3/100) were in-frame deletions, and 
1% (1/100) was an in-frame insertion.  89% (17/19) of the in-frame deletions and 
duplications occurred in the poly-alanine segment of the gene.   
The vast majority (98%) of family-specific mutations were predicted or proven 
significant loss-of-function.  Interestingly, among the very few patients whose mutations 
were not predicted null, alobar HPE was not observed and 66% (2/3) were inherited, in 
contrast to the overall estimation that 69% of mutations were de novo.  There was no 
correlation between the type, location, and functional activity conferred by a mutation 
with the presence of facial dysmorphisms or with HPE severity.   
 
 Mutations in ZIC2 are one of the two most common single-gene causes of non-
syndromic HPE (with SHH).  As patients with ZIC2 mutations may not have facial 
dysmorphisms typically associated with HPE, the diagnosis of HPE may not be obvious 
on clinical encounter.  Mutations in ZIC2 may be an underappreciated cause of HPE, 
especially in the instance of an early fetal demise when high-quality brain imaging or 
pathologic analysis is not available.   
However, our analysis of this large cohort of patients with mutations in ZIC2 
reveals several unique features resulting from mutations in this gene which distinguish 
the patients described here from patients with mutations in other HPE-associated genes.  
First, many patients with mutations in ZIC2 have a subtle but distinct dysmorphic facial 
phenotype which may help aid diagnosis. This facial appearance is unique among 
patients with HPE, and has not been seen in patients with HPE due to other genetic 
etiologies.  Second, unlike other genes associated with HPE, the majority of mutations 
occur de novo.  Our data suggests the presence of at least 4 families in which germline 
mosaicism seems to be causative of HPE in a child, which has important implications for 
genetic counseling.  Parents who test negative for ZIC2 mutations through analysis of 
peripheral blood may still be at risk for having other affected children.  
Third, along these lines, we did not identify any large pedigrees in which 
numerous individuals from multiple generations were identified, which is not the case for 
the other common HPE-associated genes such as SHH or SIX3.  This could imply that 
mutations in ZIC2 are less likely to result in mildly-affected individuals than mutations in 
other HPE-associated genes.  Since ZIC2 mutations occur relatively frequently in non-
syndromic HPE, this would further imply that the mutation rate for these mutations is 
higher than, for example, mutations in SIX3, which are overall less frequent, but occur 
more often in large kindreds with multiple affected generations
20
.  However, the high 
penetrance and relatively severe findings may bring individuals to clinical attention 
earlier, resulting in ascertainment bias.   
Finally, laboratories and clinicians must be aware of the importance of functional 
data in order to characterize mutations and to inform counseling of affected families; we 
know specifically of certain repeat variants in ZIC2 resulting in different numbers of 
histidine repeats, which have previously been thought to be pathogenic, but on later 
family analysis, are now thought to be polymorphisms which may be common in 
ethnicities not originally part of control populations
17
.  
One shortcoming of this report is that the available retrospective collection of  
clinical data was not uniform.  For this reason, it is likely that we underestimate the 
prevalence of many of the findings (such as neural tube defects and other congenital 
anomalies).  Despite the challenges synthesizing the data, the availability of a large 
cohort of patients with mutations affecting the same gene greatly enriches our 
understanding of HPE in general and ZIC2 in particular.  This study demonstrates the 
existence of a previously unnoticed  ZIC2-specific phenotype, and highlights the 
importance of a comprehensive and collaborative approach to study HPE and other 
complex genetic disorders.   
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Figure Legends 
Figure 1.  Characteristic findings on neuroimaging.  a: Alobar HPE with shunt in place; 
b,c: semilobar HPE with large dorsal cyst; d: semilobar HPE without dorsal cyst; e,f: 
MIHV-type HPE 
Figure 2.  Patients with mutations in ZIC2, arranged by HPE type.  Note ZIC2-specific 
facial findings, consisting of bitemporal narrowing, upslanting palpebral fissures, flat 
nasal bridge and a short nose with upturned nares, a broad and/or deep philtrum, and 
large ears.   
